Wireframe brain network with DNA strands and molecules in cyan light

Sanofi Infilbray Approved for Neurological Type 3 Gaucher

Table of Contents

FDA approved Sanofi’s Infilbray (venglustat), the first medicine for neurological symptoms of Type 3 Gaucher disease. Here is what the trial and label show.

Last updated: November 19, 2026

The FDA approved Infilbray (venglustat) on November 18, 2026, for neurological manifestations of Type 3 Gaucher disease in adults and children weighing at least 15 kg. It is a once daily oral glucosylceramide synthase inhibitor that crosses the blood brain barrier, and Sanofi says it is the first medicine for this use.

Scope: what was approved, the LEAP2MONO evidence, safety, how it fits next to existing Gaucher therapy, and what to watch. Figures come from Sanofi releases and FDA records unless attributed.

What did the FDA approve?

The FDA approved Infilbray (venglustat), an oral glucosylceramide synthase inhibitor, “for the treatment of neurological manifestations of Type 3 Gaucher disease (GD3) in adults and pediatric patients weighing at least 15 kg,” according to Sanofi’s November 18 release. Reuters reported the approval came on Wednesday, November 18.

The timing matters. Sanofi’s May 28 release set a target action date of November 25, 2026, under priority review, so the decision landed a week early. The drug also carried breakthrough therapy, rare pediatric disease and fast track designations in the US, and orphan designation for GD3 in the US, EU and Japan, per Sanofi.

This is the first approved therapy aimed at the brain side of Gaucher disease. Every existing Gaucher drug in the US is labeled for the body side of the disease, such as the spleen, liver and blood counts. None is labeled for the neurological disease that defines Types 2 and 3.

Why is Type 3 Gaucher disease so hard to treat?

Type 3 is the chronic neuronopathic form of Gaucher disease, and the standard treatment cannot reach the brain. Enzyme replacement therapy is a large protein given by infusion, and it does not cross the blood brain barrier in meaningful amounts.

MedlinePlus Genetics (NIH) describes Types 2 and 3 as the neuronopathic forms and says Type 3 “tends to worsen more slowly than type 2.” NORD notes that ERT does not primarily address brain related problems because of the blood brain barrier. So a patient on infusions can have a normal spleen and good blood counts while ataxia and cognitive decline progress.

Venglustat takes the other route. Instead of adding enzyme, it blocks glucosylceramide synthase, the enzyme that makes the fatty substrate that builds up in Gaucher cells. Sanofi designed it as a small molecule that crosses into the brain, which is the whole thesis of the program.

What did the LEAP2MONO trial show?

LEAP2MONO (NCT05222906) was a Phase 3, double blind, double dummy, active comparator study that randomized 43 patients aged 12 and older 1:1 to once daily oral venglustat or intravenous ERT (imiglucerase) every two weeks. Venglustat won on the prespecified neurological endpoint.

The primary endpoint was a global test combining two measures at week 52: a modified Scale for the Assessment and Rating of Ataxia (SARA) and the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) total scale index score. Sanofi reports statistically significant superiority over ERT on that global test. Per Reuters, enrolled patients had symptoms outside the nervous system already stabilized on ERT.

On the body side, Sanofi’s February 2 release said venglustat “performed as well as ERT” on spleen volume, liver volume and hemoglobin, three of four key secondary endpoints. Sanofi says the drug met three of four key secondaries but has not said which one missed. Platelet count is the remaining systemic secondary named in the trial design.

LEAP2MONO detail What Sanofi reports
Design Phase 3, double blind, double dummy, active comparator, two arms
Patients 43 randomized 1:1 (21 venglustat, 22 imiglucerase), aged 12 and older
Comparator Imiglucerase (ERT) IV every two weeks
Primary endpoint Global test of modified SARA and RBANS change at week 52
Primary result Statistically significant superiority vs ERT
Systemic endpoints Comparable to ERT on spleen volume, liver volume, hemoglobin
Key secondaries met Three of four (the miss is not named)

Two cautions for readers using these numbers. First, Sanofi has not published mean changes for the ataxia or cognition scores in its releases, so the size of the benefit is not yet public in a form we can verify. Second, the p value Sanofi cites for the global test differs between its February topline release and its approval release; we have left both out until the label or FDA review documents settle which analysis the agency relied on.

What are the safety risks?

Infilbray carries Warnings and Precautions for suicidal ideation and behavior, lens opacification in pediatric patients, and embryofetal toxicity, per Sanofi’s approval release. That mood signal is the one prescribers will watch most closely.

In the primary analysis period, adverse reactions more common on Infilbray (n=21) than imiglucerase (n=22) included:

Adverse reaction Infilbray Imiglucerase
Diarrhea 14% 0%
Splenomegaly 14% 0%
Nausea 14% 5%
Depression 10% 0%
Gastroenteritis 10% 0%
Vomiting 10% 5%

With 21 patients on drug, each percentage point is a small number of people. A 10% depression rate is roughly two patients. That is enough to earn a warning and not enough to characterize the risk well, which is why postmarketing data will matter.

How does Infilbray fit with existing Gaucher drugs?

Infilbray fills the one gap no other US Gaucher drug covers. The enzyme replacement therapies and the two older oral substrate reduction therapies all target the systemic disease.

Sanofi already owns the backbone. Cerezyme (imiglucerase), on the US market since 1994, gained a January 2026 label expansion to non CNS manifestations of Type 3 Gaucher disease, per the FDA approval letter for supplement 123. Sanofi said that expansion rested on real world evidence from the ICGG Gaucher Registry. Sanofi also markets Cerdelga (eliglustat), an oral SRT approved in 2014 for adults with Type 1 disease who have a qualifying CYP2D6 metabolizer status.

So Sanofi now has an infusion labeled for the body side of Type 3 and a pill labeled for the brain side. How prescribers combine them, and how payers cover two products for one patient, is the commercial question. Sanofi’s release does not address combination use, price or launch timing.

What does this mean for the industry?

Three reads for operators and executives. First, a brain penetrant small molecule just beat an infusion in a head to head trial on neurological endpoints, which strengthens the case for substrate reduction across other lysosomal storage disorders where the brain is the unmet need.

Second, the approval ran on 43 patients with a composite neurological endpoint. For rare disease sponsors weighing whether ataxia and cognition scales can carry a Phase 3, this is a working precedent.

Third, venglustat is not a platform win yet. Sanofi’s February release disclosed that the PERIDOT trial in Fabry disease did not meet its primary endpoint, while CARAT continues. The molecule works where brain exposure is the point; it has not proven itself everywhere.

Our checklist: what to verify on the Infilbray label

This is our framework for anyone building a formulary, launch or competitive view.

  • Recommended dose and any weight based dosing for pediatric patients under 12, who were not studied in LEAP2MONO
  • Whether the label addresses use alongside ERT or as monotherapy
  • Drug interaction section, including any CYP3A guidance
  • Ophthalmic monitoring language tied to the pediatric lens opacification warning
  • Monitoring for suicidal ideation and behavior, and whether a Medication Guide is required
  • Contraception requirements under the embryofetal toxicity warning
  • Whether a rare pediatric disease priority review voucher was issued (Sanofi has not said)
  • Postmarketing requirements and long term extension data

What to watch next

  • Publication of the US prescribing information and FDA review documents, including effect sizes for SARA and RBANS
  • Price and launch timing, which Sanofi has not disclosed
  • Decisions in the EU, Japan and other markets, where Sanofi says venglustat is under review
  • CARAT results in Fabry disease after the PERIDOT miss
  • Whether competitors move brain penetrant approaches into other neuronopathic lysosomal disorders

Frequently asked questions

What is Infilbray?

Infilbray is the brand name for venglustat, a once daily oral glucosylceramide synthase inhibitor from Sanofi. The FDA approved it on November 18, 2026, for neurological manifestations of Type 3 Gaucher disease.

Who can take Infilbray?

The indication covers adults and pediatric patients weighing at least 15 kg with Type 3 Gaucher disease, according to Sanofi. The pivotal trial enrolled patients aged 12 and older.

Is Infilbray the first treatment for neurological Gaucher disease?

Yes. Sanofi says it is the first medicine approved to treat neurological manifestations of Type 3 Gaucher disease. Existing US Gaucher therapies are labeled only for systemic, non CNS disease.

How does venglustat work?

It blocks glucosylceramide synthase, reducing production of the lipid that accumulates in Gaucher disease. Sanofi designed it to cross the blood brain barrier, which enzyme replacement infusions cannot do effectively.

What trial supported the approval?

LEAP2MONO (NCT05222906), a Phase 3 study of 43 patients randomized to oral venglustat or imiglucerase infusions every two weeks. Venglustat showed statistically significant superiority on a combined ataxia and cognition endpoint at week 52.

What are the main side effects of Infilbray?

Diarrhea, splenomegaly and nausea each occurred in 14% of patients, and depression, gastroenteritis and vomiting in 10%, per Sanofi. Warnings cover suicidal ideation and behavior, pediatric lens opacification and embryofetal toxicity.

Was the approval early?

Yes. Sanofi’s priority review target action date was November 25, 2026. The FDA acted on November 18, one week ahead.

Does Infilbray replace enzyme replacement therapy?

Not necessarily. The approved indication is specific to neurological manifestations. Sanofi reported comparable systemic results to ERT in the trial, but its release does not say how the drug should be combined with or substituted for infusions.

How much does Infilbray cost?

Sanofi has not disclosed a price or a launch date as of November 19, 2026.

Is venglustat approved outside the US?

Not yet. Sanofi says it is under regulatory review for Type 3 Gaucher disease in the EU, Japan and other jurisdictions, with more submissions planned in 2026 and 2027.

Sources

  • Sanofi, “Infilbray approved in the US as the first medicine to treat neurological manifestations of Type 3 Gaucher disease,” November 18, 2026 (primary): https://www.sanofi.com/en/media-room/press-releases/2026/2026-11-18-22-19-06-3406209
  • Sanofi, venglustat accepted for priority review, May 28, 2026 (primary): https://www.sanofi.com/en/media-room/press-releases/2026/2026-05-28-05-00-00-3302498
  • Sanofi, venglustat earns Breakthrough Therapy designation, March 18, 2026 (primary): https://www.sanofi.com/en/media-room/press-releases/2026/2026-03-18-06-00-00-3257888
  • Sanofi, venglustat met all primary endpoints in Phase 3 GD3 study, February 2, 2026 (primary): https://www.sanofi.com/en/media-room/press-releases/2026/2026-02-02-06-00-00-3229947
  • FDA approval letter, Cerezyme supplement 123, January 2026 (primary): https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/020367Orig1s123ltr.pdf
  • Cerezyme and Cerdelga prescribing information, DailyMed (primary)
  • MedlinePlus Genetics, Gaucher disease (attributed): https://medlineplus.gov/genetics/condition/gaucher-disease
  • NORD, Gaucher disease (attributed): https://rarediseases.org/rare-diseases/gaucher-disease
  • Reuters, “US FDA approves Sanofi’s genetic disorder drug,” November 18, 2026 (attributed: approval day, patient stabilization on ERT)

Related coverage

Get the daily briefing on biotech, pharma and medtech: subscribe to BioMed Nexus.

Featured Articles

Join 65,000+ Biotech, MedTech, and Pharma Leaders

Your Daily Edge in Biotech, MedTech, and Pharma

Get trusted, high-signal updates every morning
Breakthroughs, trial data, deals, and the news that matters